{"id":747287,"date":"2023-04-13T07:06:16","date_gmt":"2023-04-13T11:06:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/"},"modified":"2023-04-13T07:06:16","modified_gmt":"2023-04-13T11:06:16","slug":"axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/","title":{"rendered":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8"},"content":{"rendered":"<h2>\nAxsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  13, 2023  (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Axsome\u2019s management team will host a conference call at 8:00 a.m. Eastern Time on May 8, 2023, to discuss these results and provide a business update.<\/p>\n<p align=\"justify\">To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference call can be accessed on the \u201cWebcasts &amp; Presentations\u201d page of the \u201cInvestors\u201d section of the Company\u2019s website at <strong>www.axsome.com<\/strong>. A recording of the conference call will be available on the Company\u2019s website for approximately 30 days following the live event.<\/p>\n<p align=\"justify\">\n        <strong>About Axsome Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company\u2019s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain matters discussed in this press release are \u201cforward-looking statements\u201d. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi<sup>\u00ae<\/sup> and Auvelity<sup>\u00ae<\/sup> products and the success of our efforts to obtain any additional indication(s) with respect to solriamfetol and\/or AXS-05; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, our product candidates; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company\u2019s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the Company\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company\u2019s research and development programs and collaborations; the success of the Company\u2019s license agreements; the acceptance by the market of the Company\u2019s products and product candidates, if approved; the Company\u2019s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company\u2019s commercial launch of its other product candidates, and the potential impact on the Company\u2019s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.<\/p>\n<p>\n        <strong>Axsome Contacts: <\/strong><br \/>\n        <br \/>Investors:<br \/>Mark Jacobson<br \/>Chief Operating Officer<br \/>Axsome Therapeutics, Inc.<br \/>22 Cortlandt Street, 16<sup>th<\/sup>\u00a0Floor<br \/>New York, NY\u00a010007<br \/>Tel: 212-332-3243<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4V3q8dRj3KNsrVBSSRs-Q_QbfdW-IDR0XXO1cNZwUfxbUCnQGeADq4lsC899UymJXgbCqF5Y7WLZa82JChbWenCWorK3EqCnMrRI2rtQT7s=\" rel=\"nofollow noopener\" target=\"_blank\">mjacobson@axsome.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8VOUwDs2LYKIKLsXl-ZiiMy446Z1uDxk7uBr06rVa49s8BTBtcgnDWMvkpjseSkqGe1e3gXugdoYvUXcEakwdfIl9lEGZVW86TFw9_3tpChOSC8nESLe1l6OXtrEcLaUX8Qx4bLnGEQT_W1hNKSvIpfyNy5JM1sF7CD4T50dnogaJERjX-uK1gKK0u_tLulO\" rel=\"nofollow noopener\" target=\"_blank\">www.axsome.com<\/a><\/p>\n<p>Media:<br \/>Darren Opland<br \/>Director, Corporate Communications <br \/>Axsome Therapeutics, Inc.<br \/>22 Cortlandt Street, 16<sup>th<\/sup> Floor<br \/>New York, NY 10007<br \/>Tel: 929-837-1065<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=chsaWfLsCXqX0zVaIIfp9NcCiUkxnUf6ipFKUC5e11Q-tJvyzfVpfQ2tWB7aIjWjwwFcFxGqZtVCzave7srRtF4LJdcH97nEKMPg0p59ByM=\" rel=\"nofollow noopener\" target=\"_blank\">dopland@axsome.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8VOUwDs2LYKIKLsXl-ZiiMQm3hdxJXJS2W4YIdYai7Sz6oOUGUx_UOIKc83naOsy2fB5HFOyWyUGZSvsvQ1QYg==\" rel=\"nofollow noopener\" target=\"_blank\">www.axsome.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWM2YzQwMDUtNzMzYS00ZDVkLTliM2EtNzEzMDg3ZmRjNmQ0LTEwMzAxMzA=\/tiny\/Axsome-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Axsome\u2019s management team will host a conference call at 8:00 a.m. Eastern Time on May 8, 2023, to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-747287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Axsome\u2019s management team will host a conference call at 8:00 a.m. Eastern Time on May 8, 2023, to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference &hellip; Continue reading &quot;Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T11:06:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8\",\"datePublished\":\"2023-04-13T11:06:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/\",\"name\":\"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\",\"datePublished\":\"2023-04-13T11:06:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/","og_locale":"en_US","og_type":"article","og_title":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk","og_description":"Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Axsome\u2019s management team will host a conference call at 8:00 a.m. Eastern Time on May 8, 2023, to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference &hellip; Continue reading \"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-13T11:06:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8","datePublished":"2023-04-13T11:06:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/"},"wordCount":804,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/","name":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=","datePublished":"2023-04-13T11:06:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjc1NiM1NTIzMjQwIzIwMTg1NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=747287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=747287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=747287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=747287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}